Abstract 6560: Sann-Jhong-Kuey-Jian-Tang could inhibit glioblastoma cells through increasing TNF-α, Fas, Bax but decreasing Bcl-2, Mcl-1 expression

Abstract

Abstract Glioblastoma is a highly malignant brain tumor and poor response to current chemotherapeutic medicine (such as Temozolomide). Glioblastoma remains a challenging disease and there is a need to identify new treatments. Sann-Jhong-Kuey-Jian-Tang (SJKJT), a traditional Chinese medicine prescription, has been prescribed as complementary medicine for patients with solid tumors in Taiwan. However, the anticancer effects of SJKJT on human brain tumor have not yet been elucidated. The present study focused on the anticancer effects and molecular mechanisms of SJKJT in human Glioblastoma by using DBTRG cells. In the present study, we evaluated the cytotoxic effects of SJKJT on DBTRG cells by MTT assay. The protein expression levels of tumor necrosis factor-α (TNF-α), Fas, Fas-associated Death Domain (FADD), Caspase-8, Caspase-9, Caspase-3, Bcl-2-associated X protein (Bax), Bcl-2 and myeloid cell leukemia 1 protein (Mcl-1) in the DBTRG cells were measured by western blotting. The cell cycles were analyzed by fluorescence-activated cell sorting (FACS). The protein expression of caspase-3 in DBTRG cells was analyzed by immunocytochemical (ICC) method. The results revealed that SJKJT inhibit the proliferation of DBTRG cells in a time- and dose-dependent manner. The protein expression levels of TNF-α, Fas, FADD, Caspase-8, Caspase-9, Caspase-3, Bcl-2-associated X protein (Bax) increased in the DBTRG cells treated with SJKJT; however, the level of Bcl-2 and Mcl-1 were decreased. These results indicated that SJKJT can inhibit DBTRG cells through both extrinsic and intrinsic pathway. The use of traditional Chinese medicine prescription SJKJT may become a feasible therapy option. Further studies are warranted to elucidate its mechanisms of action. Citation Format: Chin Cheng Su. Sann-Jhong-Kuey-Jian-Tang could inhibit glioblastoma cells through increasing TNF-α, Fas, Bax but decreasing Bcl-2, Mcl-1 expression [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 6560.